Published in Gene Therapy Weekly, November 26th, 2009
"We previously developed a technology for condensing a single gene into a single and stable globular nanometric system. In this manuscript, we have decorated the nanometric particles with cyclic RGD ligands in order to target endothelial cells," wrote G. Zuber and colleagues, University of Strasbourg.
The researchers concluded: "The potential of these artificial viruses as targeted gene delivery vehicles is demonstrated in vitro with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2009-11-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.